Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2004

View Archived Issues

atugen and Aventis collaborate in identifying siRNA compounds

Medarex and diaDexus expand collaboration into cancer antibody therapeutics

Update on Sinovac's split flu vaccine

Second performance milestone in Lexicon/Genentech drug discovery alliance

Vernalis and Novartis complete Hsp90 license agreement

Sumitomo licenses Japanese rights to repaglinide

Update on Endo's oxymorphone program

Metabolic completes dosing in AOD-9604 phase IIb trial

Two series of HDAC inhibitors presented by Roche researchers

New vanilloid VR1 ligands for pain and ulcerative colitis

Pfizer scientists describe new cannabinoid CB1 antagonists

Novel cytochrome b5 inhibitors and their use in sickle cell disease

New methionyl-tRNA synthetase inhibitors claimed by Replidyne

Predix patent covers 5-HT1A receptor modulators for anxiety, ADD and sexual dysfunction

Novel CDK4 inhibitors in early development at Roche

Novel gamma-secretase inhibitors prepared and tested at Roche

Medarex and Pfizer form global collaboration to create fully human antibody products

ML Laboratories licenses rights to budesonide Clickhaler

Potent antiviral agent brings new insight into enterovirus 71 drug-resistance mechanism

Small-molecule inhibitor of beta-catenin/cyclic AMP effective in models of colon cancer

Prous Science announces publication of a comprehensive review on narcolepsy

Novel somatostatin analogue shows analgesic effects in vivo

Oncology collaboration between Ablynx and Genencor

Oxford BioMedica extends agreement for cytochrome P450 enzymes

Last volunteers to be enrolled in phase I HIV vaccine trial

Acambis to submit BLA for ACAM-2000 smallpox vaccine after removal of FDA's clinical hold on trials

U.S. Army to evaluate Pharming's recombinant human fibrinogen product

hBNP formulation affects arterial pressure in dogs

Serotonin receptor a possible target for allergic disease treatment

Fibromyalgia patients benefit from duloxetine treatment

3-Aminobenzamide offers neuroprotection in stroke model

PPARgamma chemoprotective for mammary, ovarian and skin cancers

BAY-58-2667 plus BNP beneficial in CHF model

Millennium reports development pipeline and marketed product progress

Xenova tracks progress of key programs in year to date

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...